FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Moorin Jay 		2. Issuer Name and Ticker or Trading Symbol

AGILE THERAPEUTICS INC [ AGRX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O PROQUEST INVESTMENTS, 2430 VANDERBILT BEACH ROAD, #108 - 190 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/29/2014
(Street)

NAPLES, FL 34109
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/29/2014     C    164417   A   (2) 167140   I   See footnote   (1)
Common Stock   5/29/2014     C    1950200   A   (2) 2117340   I   See footnote   (7)
Common Stock   5/29/2014     C    460350   A   (2) 2577690   I   See footnote   (8)
Common Stock   5/29/2014     C    158174   A $6.00   2735864   I   See footnote   (9)
Common Stock   5/29/2014     P    1120833   A $6.00   3856697   I   See footnote   (10)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A-1 Preferred Stock     (2) 5/29/2014     C         117441      (2)   (2) Common Stock   164417   $0   0   I   See footnote   (1)
Series B Preferred Stock     (2) 5/29/2014     C         1393000      (2)   (2) Common Stock   1950200   $0   0   I   See footnote   (3)
Series C Preferred Stock     (2) 5/29/2014     C         328821      (2)   (2) Common Stock   460350   $0   0   I   See footnote   (4)
Warrants (right to buy)   $10.00   5/29/2014     J   (11)       141825    12/30/2009   12/30/2019   Series A-1 Preferred Stock   141825   $0   0   I   See footnote   (1)
Convertible Subordinated Notes   $6.00   5/29/2014     C         $942540.84      (5)   (5) Common Stock   158174   $0   $0   I   See footnote   (6)

Explanation of Responses:
( 1)  Owned by ProQuest Investments III, L.P.
( 2)  This class of preferred stock (i) converted on a 1.4-for-1 basis automatically upon the closing of the Issuer's initial public offering and (ii) had no expiration date.
( 3)  Of such shares, 1,400,000 are owned by ProQuest Investments III, L.P. and 550,200 are owned by ProQuest Investments IV, L.P.
( 4)  Of such shares, 330,486 are owned by ProQuest Investments III, L.P. and 129,864 are owned by ProQuest Investments IV, L.P.
( 5)  The notes converted automatically upon the Issuer's initial public offering. Absent conversion, the notes mature on the earier of (a) 10 days after written demand by a majority of the holders of the class of notes occuring after August 1, 2014, (b) consummation of a sale transaction as defined in the notes or (c) liquidation, dissolution or winding up of the Issuer.
( 6)  Of such amount, $676,652.12 is owned by ProQuest Investments III, L.P. and $265,888.72 is owned by ProQuest Investmemts IV, L.P.
( 7)  Of such shares, 1,567,140 are owned by ProQuest Investments III, L.P. and 550,200 are owned by ProQuest Investments IV, L.P.
( 8)  Of such shares, 1,897,626 are owned by ProQuest Investments III, L.P. and 680,064 are owned by ProQuest Investments IV, L.P.
( 9)  Of such shares, 2,011,179 are owned by ProQuest Investments III, L.P. and 724,685 are owned by ProQuest Investments IV, L.P.
( 10)  Of such shares, 2,677,846 are owned by Proquest Investements III, L.P. and 1,178,851 are owned by ProQuest Investments IV, L.P.
( 11)  Warrants expired unexercised for no value.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Moorin Jay
C/O PROQUEST INVESTMENTS
2430 VANDERBILT BEACH ROAD, #108 - 190
NAPLES, FL 34109
X

SCHREIBER ALAIN
C/O PROQUEST INVESTMENTS
2430 VANDERBILT BEACH ROAD, #108 - 190
NAPLES, FL 34109
X

ProQuest Investments III, L.P.
2430 VANDERBILT BEACH ROAD, #108 - 190
NAPLES, FL 34109
X

ProQuest Associates III LLC
2430 VANDERBILT BEACH ROAD, #108 - 190
NAPLES, FL 34109
X

ProQuest Investments IV, L.P.
2430 VANDERBILT BEACH ROAD, #108 - 190
NAPLES, FL 34109
X

ProQuest Associates IV LLC
2430 VANDERBILT BEACH ROAD, #108 - 190
NAPLES, FL 34109
X


Signatures
/s/ Pasquale DeAngelis 6/2/2014
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024 Agile Therapeutics 차트를 더 보려면 여기를 클릭.
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024 Agile Therapeutics 차트를 더 보려면 여기를 클릭.